Nevro Corp. NVRO recently announced that UnitedHealthcare — one of the businesses of UnitedHealth Group UNH — will offer coverage for Nevro’s high-frequency 10 kHz Therapy for treating PDN (Painful Diabetic Neuropathy) for dates of service on or after Mar 1, 2022. Interestingly, UnitedHealthcare is the largest private health insurance company in the United States.It is worth mentioning that UnitedHealth Group is a diversified health care company, offering coverage for above 39 million commercial health care members.This announcement is likely to provide a boost to Nevro’s already robust position in the spinal cord stimulation (SCS) market.More on the NewsPer management at Nevro, UnitedHealthcare’s speedy coverage decision comes following Nevro’s submission to the latter’s medical policy team in late 2021. For Nevro, this marks a huge milestone as it will facilitate access to its proprietary 10 kHz Therapy for PDN patients.Image Source: Zacks Investment ResearchAccording to management, on the back of the only SCS system that is FDA approved for the treatment of PDN, the company is well-poised to treat numerous patients suffering from the impact of PDN with a proven non-drug option.When it comes to future coverage decisions by other major health plans in 2022 and further, management believes that its solid and growing body of published, peer-reviewed clinical and real-world data will play a crucial role.Market ProspectsPer a report by Research and Markets, the global PDN market was worth $4.81 billion in 2017 and is anticipated to reach $8.96 billion by 2026, witnessing a CAGR of 6.6% during the forecast period (2018-2026). An ever-increasing pool of geriatric population with diabetes is the primary factor driving this market’s growth. Thus, this announcement comes at an opportune time for Nevro.Recent Notable DevelopmentIn November 2021, the company announced three important clinical data publications for treating PDN with 10 kHz Therapy, including 12-month data from the landmark SENZA-PDN RCT published online in Diabetes Care. The company announced real-world evidence and a comparative literature review of high versus low-frequency SCS evidence, both published in the Journal of Diabetes Science and Technology. Findings from all three studies highlight the significant benefits of HFX for PDN in clinical and real-world settings.Price PerformanceShares of the Zacks Rank #3 (Hold) company have lost 46.7% in the past year against the industry’s growth of 8.6%.Stocks to ConsiderSome better-ranked stocks in the broader medical space include Thermo Fisher Scientific Inc. TMO and Abiomed, Inc. ABMD.Thermo Fisher surpassed earnings estimates in each of the trailing four quarters, the average surprise being 9.02%. The company currently carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Thermo Fisher’s long-term earnings growth rate is estimated at 14%. The company’s earnings yield of 3.7% compares favorably with the industry’s (3.6%).Abiomed beat earnings estimates in each of the trailing four quarters, the average surprise being 5.8%. The company currently carries a Zacks Rank #2.Abiomed’s long-term earnings growth rate is estimated at 20%. The company’s earnings yield of 1.2% compares favorably with the industry’s (3.6%). Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Nevro Corp. (NVRO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research